D-0358-2022 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0358-2022 was initiated by Lupin Pharmaceuticals Inc. on Dec 29, 2021 and is designated Class III. Reason for recall: Out-of-specification impurity test result observed at 18-month long term stability time point. The recall status is terminated (terminated Aug 23, 2022). Affected quantity: 23,965 100 count bottles.

Recall details

Product Type
Drugs
Report Date
Jan 12, 2022
Initiation Date
Dec 29, 2021
Termination Date
Aug 23, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
23,965 100 count bottles

Product description

Oxycodone Hydrochloride Tablets, USP C-II, 5 mg, 100 count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202. Manufactured by: Novel Laboratories, Inc. Somerset, NJ 08873. NDC 43386-432-01

Reason for recall

Out-of-specification impurity test result observed at 18-month long term stability time point.

Distribution pattern

Product Distributed in NY and OH.

Code information

Lot # S000268, Exp. date January 2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0358-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0358-2022. Report a data issue: hello@regdatalab.com.